@article{JGO604,
author = {Nadia K Malik and Kilian Salerno May and Rameela Chandrasekhar and Wen Wee Ma and Leayn Flaherty and Renuka Iyer and John Gibbs and Boris Kuvshinoff and Gregory Wilding and Graham Warren and Gary Y Yang},
title = {Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience},
journal = {Journal of Gastrointestinal Oncology},
volume = {3},
number = {4},
year = {2012},
keywords = {},
abstract = {Purpose: We retrospectively analyzed the results of patients with locally advanced unresectable pancreatic cancer (LAPC) treated with either chemoradiation (CRT) or chemotherapy alone over the past decade. Methods and materials: Between December 1998 and October 2009, 116 patients with LAPC were treated at our institution. Eighty-four patients received concurrent chemoradiation [RT (+) group], primarily 5-flourouracil based (70%). Thirty-two patients received chemotherapy alone [RT (-) group], the majority gemcitabine based (78%). Progression-free survival (PFS) and overall survival (OS) were calculated from date of diagnosis to date of first recurrence and to date of death or last follow-up, respectively. Univariate statistical analysis was used to determine significant prognostic factors for overall survival. Results: Median patient age was 67 years. Sixty patients were female (52%). Median follow-up was 11 months (range, 1.6-59.4 months). The RT (+) group received a median radiation dose of 50.4 Gy, was more likely to present with ECOG 0-1 performance status, and experienced less grade 3-4 toxicity. PFS was 10.9 versus 9.1 months (P=0.748) and median survival was 12.5 versus 9.1 months (P=0.998) for the RT (+) and RT (-) groups respectively (P=0.748). On univariate analysis, patients who experienced grade 3-4 toxicity had worse overall survival than those who did not (P=0.02). Conclusions: Optimal management for LAPC continues to evolve. Patients who developed treatmentrelated grade 3-4 toxicity have a poorer prognosis. Survival rates were not statistically significant between chemotherapy and chemoradiotherapy groups.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/604}
}